Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Novel agents versus chemotherapy as frontline treatment of CLL.

Leukemia & lymphoma - 1 Jun 2017

Piggin Anna, Bayly Emma, Tam Constantine S

Abstract excerpt

Chronic lymphocytic leukemia (CLL) is a neoplastic disorder of mature B lymphocytes. While traditionally treated with combinations of chemoimmunotherapy, the therapeutic options for CLL have expanded in recent years with the emergence of novel oral agents, such as the Bruton tyrosine kinase inhibitor ibrutinib, that are well tolerated and highly efficacious. The role of novel agents in the first-line setting is...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenine
Share to Chromosomes, Human, Pair 11
Share to Chromosomes, Human, Pair 13

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Clinical Trials as Topic

Share to Immunoglobulin Heavy Chains

Share to Leukemia, Lymphocytic, Chronic, B-Cell

Share to Piperidines

Share to Pyrazoles

Source

Identifiers

PMID: 28271950
DOI: 10.1080/10428194.2017.1280606

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026. Manifest publication-graph-cohort-2026-09-06.1.

Source receipt: pubmed, retrieved 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Novel agents versus chemotherapy as frontline treatment of CLL.PMID 28271950Read ↗

Optimizing frontline therapy of CLL based on clinical and biological factors.Semantic proximity Read ↗

Novel Therapies in Chronic Lymphocytic Leukemia: A Rapidly Changing Landscape.Semantic proximity Read ↗

How should we sequence and combine novel therapies in CLL?Semantic proximity Read ↗

The Role of Bruton’s Kinase Inhibitors in Chronic Lymphocytic Leukemia: Current Status and Future DirectionsSemantic proximity Read ↗

A Review of Resistance Mechanisms to Bruton's Kinase Inhibitors in Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Comparison Between Venetoclax-based and Bruton Tyrosine Kinase Inhibitor-based Therapy as Upfront Treatment of Chronic Lymphocytic Leukemia (CLL): A Systematic Review and Network Meta-analysis.Semantic proximity Read ↗

Ibrutinib treatment of CLL: the cancer fights back.Semantic proximity Read ↗

SOHO State of the Art Updates and Next Questions: Updates on BTK Inhibitors for the Treatment of Chronic Lymphocytic Leukemia.Semantic proximity Read ↗

Ibrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and ProspectsSemantic proximity Read ↗

Pirtobrutinib at the Crossroads: Shaping Its Future Role in Chronic Lymphocytic Leukemia (CLL) Care.Semantic proximity Read ↗

Update on therapy of chronic lymphocytic leukemia.Semantic proximity Read ↗

Targeting Bruton's Tyrosine Kinase in CLL.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.